Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/30/2025 | $662.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/30/2025 | $580.00 | Overweight → Equal Weight | Wells Fargo |
| 5/14/2025 | $700.00 | Neutral → Buy | Citigroup |
| 4/22/2025 | $695.00 | Overweight | Cantor Fitzgerald |
| 2/5/2025 | $762.00 → $834.00 | Market Perform → Outperform | Leerink Partners |
| 1/16/2025 | $1130.00 → $738.00 | Buy → Neutral | UBS |
| 12/10/2024 | $565.00 | Underperform | BofA Securities |
| 11/15/2024 | $1150.00 | Outperform | Wolfe Research |
RBC Capital Mkts downgraded Regeneron Pharma from Outperform to Sector Perform and set a new price target of $662.00
Wells Fargo downgraded Regeneron Pharma from Overweight to Equal Weight and set a new price target of $580.00
Citigroup upgraded Regeneron Pharma from Neutral to Buy and set a new price target of $700.00